Innovative Methodologies to Drive Enrollment of Molecularly Defined Patient Populations for Diagnostic- Enabled Basket Studies


Today, the genomic profile of a patient’s tumor may be as important, if not more so, than the tissue of origin. Patients whose tumors harbor certain oncodrivers (e.g., HER2, EGFR, ALK) have significantly more effective treatment options at their disposal than they did just five years ago. Genomic information from next generation sequencing (NGS) panels has led to deeper understanding of tumor biology, often leading to reclassification of disease based on molecular biology rather than tissue of origin.1